

Date 10/02/2026
Your Ref
Our Ref 11036

Enquiries to Richard Mutch
Extension 35687
Direct Line 0131 465 5687
loth.freedomofinformation@nhs.scot
richard.mutch@nhs.scot

Dear

FREEDOM OF INFORMATION – DIFFUSE LARGE B CELL LYMPHOMA

I write in response to your request for information in relation to Diffuse Large B Cell Lymphoma prescribing

Question:

1. In the last 6 months, how many patients have been diagnosed with Diffuse Large B Cell Lymphoma (DLBCL)?

Answer:

53

Question:

- 1a. Of these patients, how many commenced treatment at your trust within the last 6 months?

Answer:

40

Question:

2. In the last 6 months, how many patients have you treated for Diffuse Large B Cell Lymphoma (DLBCL) with the following treatments:
 - a. R-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone)
 - b. R-mini-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone)
 - c. Pola-BR (polatuzumab vedotin with rituximab and bendamustine)
 - d. Pola-R-CHP (Polatuzumab vedotin with rituximab, cyclophosphamide, doxorubicin hydrochloride, and prednisolone)
 - e. R-CODOX-M (rituximab, cyclophosphamide, vincristine, doxorubicin and methotrexate)
 - f. R-IVAC (rituximab, ifosfamide, etoposide and cytarabine)
 - g. R-GCVP (Rituximab, gemcitabine, cyclophosphamide, vincristine, prednisolone)
 - h. (DA)-EPOCH +/-R (Prednisolone, doxorubicin, vincristine, etoposide, cyclophosphamide, rituximab)

Headquarters
Mainpoint
102 West Port
Edinburgh EH3 9DN

Chair Professor John Connaghan CBE
Chief Executive Professor Caroline Hiscox
Lothian NHS Board is the common name of Lothian Health Board

- i. R-GemOX (rituximab, gemcitabine and oxaliplatin)
- j. Axicabtagene ciloleucel
- k. Tisagenlecleucel
- l. Epcoritamab
- m. Loncastuximab tesirine
- n. Glofitamab
- o. Any other SACT
- p. Stem cell transplant or bone marrow transplant (autologous or allogeneic)

Answer:

a.	39
b.	11
c.	6
d.	12
e.	0
f.	0
g.	0
h.	0
i.	0
j.	5 or fewer
k.	0
l.	0
m.	5 or fewer
n.	0
o.	45
p.	requires linkage

Question:

3. In the last 6 months, how many patients have received the following 2nd line treatments for Diffuse Large B Cell Lymphoma (DLBCL):
- a. Axicabtagene ciloleucel (Yescarta)
 - b. Tisagenlecleucel
 - c. Pola-BR (polatuzumab vedotin with rituximab and bendamustine)
 - d. R-GemOX (rituximab, gemcitabine and oxaliplatin)
 - e. Stem cell transplant or bone marrow transplant (autologous or allogeneic)
 - f. Glofitamab
 - g. Any other treatments

Answer:

a.	5 or fewer
b.	0
c.	5 or fewer



d.	0
e.	requires linkage
f.	0
g.	25

To protect the identity of the individuals involved any figure of 5 or less has not been shown in the tables above. Since we do not have their consent to release this data from their records, the information is exempt under section 38(1)(b) of the Freedom of Information (Scotland) Act i.e. to provide it would breach the Data Protection Act (2018).

Question:

4. In the last 6 months, how many patients has the Trust treated for 3rd line Diffuse Large B Cell Lymphoma (DLBCL)?

Answer:

19

Question:

5. In the last 6 months, how many patients have you referred to other trusts for the treatment of Diffuse Large B Cell Lymphoma (DLBCL) for the following treatments:

- a. CAR-T Therapy (E.g. Axicabtagene ciloleucel)
- b. Stem cell transplant or bone marrow transplant (autologous or allogeneic)
- c. Any other treatment

Answer:

a.	0
b.	0
c.	0

I hope the information provided helps with your request.

If you are unhappy with our response to your request, you do have the right to request us to review it. Your request should be made within 40 working days of receipt of this letter, and we will reply within 20 working days of receipt. If our decision is unchanged following a review and you remain dissatisfied with this, you then have the right to make a formal complaint to the Scottish Information Commissioner within 6 months of receipt of our review response. You can do this by using the Scottish Information Commissioner's Office online appeals service at www.itspublicknowledge.info/Appeal. If you remain dissatisfied with the Commissioner's response you then have the option to appeal to the Court of Session on a point of law.



If you require a review of our decision to be carried out, please write to the FOI Reviewer at the email address at the head of this letter. The review will be undertaken by a Reviewer who was not involved in the original decision-making process.

FOI responses (subject to redaction of personal information) may appear on NHS Lothian's Freedom of Information website at: <https://org.nhslothian.scot/FOI/Pages/default.aspx>

Yours sincerely

ALISON MACDONALD
Executive Director, Nursing
Cc: Chief Executive